MI

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

Retrieved on: 
Thursday, February 18, 2021
Health sciences, Health, Clinical research, Design of experiments, Drug discovery, Pharmaceutical industry, Medical research, Disability, Presbyopia, Clinical trial

We believe that the combination of Nyxol and low-dose pilocarpine has an ideal product profile to become a promising treatment for presbyopia.

Key Points: 
  • We believe that the combination of Nyxol and low-dose pilocarpine has an ideal product profile to become a promising treatment for presbyopia.
  • VEGA-1 is a double-masked, randomized, placebo-controlled, multi-center trial designed to evaluate 0.75% Nyxol in combination with low dose (0.4%) pilocarpine for treatment of presbyopia.
  • Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia.
  • Please visit www.clinicaltrials.gov to learn more about Ocuphires completed Phase 2 clinical trials and ongoing Phase 3 registration trials ( NCT04620213 and NCT04638660 ), Phase 2 trial in presbyopia ( NCT04675151 ) and soon to recruit Phase 2 trial in DR/DME ( NCT04692688 ).

Gentherm Postpones 2020 Fourth Quarter and Full-Year Earnings Release and Conference Call Announces Fourth Quarter and Full-Year 2020 Revenue Results

Retrieved on: 
Thursday, February 18, 2021
Energy harvesting, Articles, Fundamental analysis, Energy conversion, Gentherm Incorporated, Heating, ventilation, and air conditioning, Earnings before interest, taxes, depreciation and amortization, Forward-looking statement, Economy

Gentherm hasmore than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea,NorthMacedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam.For more information, go to www.gentherm.com .

Key Points: 
  • Gentherm hasmore than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea,NorthMacedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam.For more information, go to www.gentherm.com .
  • These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events.
  • In evaluating its business, the Company considers and uses this non-GAAP financial measure as a supplemental measure of its operating performance.
  • Non-GAAP measures referenced in this release and other public communications may include estimates of future Adjusted EBITDA.

OptimizeRx Sets Fourth Quarter and Full Year 2020 Conference Call for Wednesday, February 24, 2021 at 4:30 p.m. ET

Retrieved on: 
Thursday, February 18, 2021
Communication, Forward-looking statement, Income, Financial statements

OptimizeRx management will host the call, followed by a question and answer period.

Key Points: 
  • OptimizeRx management will host the call, followed by a question and answer period.
  • As earlier reported , the company expects to report record revenue for the quarter of more than $16 million, up 117% from the same year-ago quarter, along with positive GAAP net income.
  • The full financial results for the quarter and full year 2020 will be issued in a press release prior to the call.
  • We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Commercial National Financial Corporation Announces Quarterly Dividend

Retrieved on: 
Thursday, February 18, 2021
Financial markets, Finance, Corporate finance, Dividends, Financial ratios, Stock market, Shareholders, Equity securities, Share, Ex-dividend date

ITHACA, Mich., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Commercial National Financial Corporation (Pink Sheets: CEFC) announced that the Board of Directors declared a regular quarterly cash dividend of 14 cents per share.

Key Points: 
  • ITHACA, Mich., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Commercial National Financial Corporation (Pink Sheets: CEFC) announced that the Board of Directors declared a regular quarterly cash dividend of 14 cents per share.
  • The dividend is payable April 1, 2021 to shareholders of record on March 19, 2021.
  • Based on a recent closing price of $9.55 per share, the annualized dividend yield is 5.86%.

Date Change for Earnings Press Release and Conference Call

Retrieved on: 
Wednesday, February 17, 2021
Telecommunications, Television networks, Starz Entertainment Group, Starz Encore, Audit, Lluís Companys, Conference call, Television

Conference Call Replay (Encore) available through Saturday, February 27, 2021

Key Points: 
  • Conference Call Replay (Encore) available through Saturday, February 27, 2021
    The Company has changed the date of the earnings press release and conference call to coincide with the release of the Companys Form 10-K and completion of the external audit.
  • Dick Gauthier, Vice President of Business Outreach, 616-365-1555

Stryker to participate in the 41st Annual Cowen Health Care Conference

Retrieved on: 
Wednesday, February 17, 2021
Video game characters, Fictional characters, Kalamazoo, Michigan, Stryker, New York Stock Exchange

Kalamazoo, Michigan, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 41st Annual Cowen Health Care Conference on Tuesday, March 2, 2021.

Key Points: 
  • Kalamazoo, Michigan, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 41st Annual Cowen Health Care Conference on Tuesday, March 2, 2021.
  • Preston Wells, Vice President, Investor Relations and Andy Pierce, Group President, MedSurg & Neurotechnology, will represent the Company in a virtual presentation scheduled for 10:30 a.m. Eastern Time.
  • A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com .
  • Stryker is one of the worlds leading medical technology companies and, together with its customers, is driven to make healthcare better.